| Date | Title | Description |
| 24.12.2025 | Syremis Therapeutics Launches With $165 Million Series A Funding To Advance New Schizophrenia And Depression Drug Programs | Syremis Therapeutics, a clinical-stage biopharmaceutical company focused on mental health, has launched with $165 million in Series A financing to advance a neuropsychiatric pipeline rooted in clinically validated biology. The round was co-... |
| 19.12.2025 | Syremis Therapeutics Raises $165M in Series A Financing | Syremis Therapeutics, a Tel Aviv, Israel, and Boston, Massachusetts-based clinical-stage biopharmaceutical company developing novel medicines for the treatment of mental health, launched with $165m Series A financing.
The round was co-led b... |
| 27.02.2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term
When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| 20.02.2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| 15.02.2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know:
– Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture
In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 26.06.2023 | Pharvaris obtains $70 million in a private placement round | |
| 28.07.2022 | Life Sciences Investor Genoa Ventures Raises $84 Million Second Fund | Venture firm Genoa Ventures has topped its fundraising goal for its second fund, raising $84 million to invest in diagnostics, agriculture and other life sciences sectors outside drug development.
Healthcare venture capital fundraising has ... |
| 11.07.2022 | RUA Life Sciences announces revenue growth to £1.6m | RUA Life Sciences announced revenue growth to £1.6m for the year ended 31 March 2022. Its revenue growth was £1.5m in 2021. |
| 01.06.2022 | MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders | SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Life Itself Conference – MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and treat psychiatric and neurological disorder... |
| 25.04.2022 | Indiana life sciences companies landed $15B in funding in 2021 | - |
| 31.03.2022 | SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering | NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of canc... |
| 30.03.2022 | London-listed life sciences firm agrees £150m debt financing facility with HSBC | Life Science REIT has agreed a £150m debt financing facility with HSBC, in a bid to fund new life science properties across the Golden Triangle: London, Oxford and Cambridge. |
| 29.03.2022 | Life Sciences and Healthcare Leader ConcertAI Raises $150 Million Series C from Sixth Street at $1.9 Billion Valuation | ConcertAI, LLC (ConcertAI), the leader in enterprise AI and real-world data (RWD) solutions for life sciences and healthcare, announced the close of its $150 million Series C investment from Sixth Street, a leading global investment firm, a... |
| 21.02.2022 | Warburg Pincus to invest $210 mn in medical devices firm Micro Life Sciences | New York-based private equity player Warburg Pincus, through its Dutch affiliate South Elm Investments B.V., has signed a definitive agreement to invest approximately $210 million (~ Rs 1,500 crore) for a minority stake in Micro Life Scienc... |
| 30.08.2021 | Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months | MEMPHIS, Tenn., Aug. 30, 2021 /PRNewswire/ -- Innovative US based biotech company Triad Life Sciences, Inc (Triad or the Company), is pleased to announce the completion of a successful A$25 million funding round which saw strong support fro... |
| 09.04.2021 | CM LIFE SCIENCES III INC.
CM Life Sciences III Inc. : Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering | CM Life Sciences III Inc. (the “Company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-a... |
| 07.04.2021 | CM Life Sciences III Inc. :, Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $480 Million Initial Public Offering | CM Life Sciences III Inc. (the “Company”) announced today that it priced its initial public offering of 48,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol ... |
| 22.02.2021 | CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering | NEW YORK–(BUSINESS WIRE)–Feb 22, 2021–
CM Life Sciences II Inc. (the “ Company ”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“ Na... |
| 27.01.2021 | Narrow River Management Announces Formation and Financing of Two New Companies Developing Therapies for Renal Diseases | NEW YORK (PRWEB) January 27, 2021
Narrow River Management (“Narrow River”) today announced the formation and completion of a Series A financing for two new companies – River 2 Renal Corp. (“R2R”) and River 3 Renal Corp. (“R3R”). Each compan... |
| 03.01.2021 | Life Sciences Firm OrbiMed Raises $3.5B Across Private Investment Funds | What You Should Know:
Life sciences investment firm OrbiMed announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners I... |
| 01.08.2019 | Life sciences VC firm Vida Ventures raises $600 million in second fund | The Boston-based venture capital firm Vida Ventures snagged $600 million more to invest in early-stage biotech companies in a second fund, it announced Thursday.
That fund should bolster the firm’s attempts to become a more significant play... |
| 18.12.2017 | Bain Capital Life Sciences Leads $70M Series B for Aptinyx | Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding c... |
| 29.09.2017 | Pfizer spin-off SpringWorks embraces shelved therapies | Sometimes science is an uncooperative friend that doesn’t play nice with corporate strategies. Promising molecules can bottom out during development – potential oncology or cardiovascular disease drugs may move the needle in those indicatio... |
| 02.05.2017 | Teewinot Life Sciences Receives $12.3M |
TAMPA, FL, Teewinot Life Sciences, a developer of cannabinoid-focused therapeutics, raised $12.3 million in Series B funding.
>> Click here for more funding data on Teewinot Life Sciences
>> To export Teewinot Life Sciences ... |
| 26.08.2016 | Perpetual life sciences investor Sofinnova raises nearly $600M | Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has announced a pooling of $595 million as its latest investor effort.
This is just s... |
| 02.06.2016 | Life Sciences Partners closes latest fund at $280m | European specialist investor Life Sciences Partners has closed its latest life sciences fund at its $280m hard cap. LSP |
| 01.06.2016 | Boston VC SV Life Sciences raises $274M toward its sixth startup fund | SV Life Sciences has raised well over half of the $400 million it announced it was seeking last year for its sixth life science upstart fund--but this falls below previous targets that have been around the $500 million mark.
The VC firm, wh... |
| 27.05.2016 | SV Life Sciences raises $273.5m for Fund VI | Specialist venture capital firm SV Life Sciences has moved past the halfway mark for its $400m-targeting sixth fund, A |
| 28.05.2015 | New fund: SV Life Sciences raising $400M for biotech, health IT startups | Historically, SV Life Sciences has invested about 40 percent of its funds in growth or later-stage deals, primarily in healthcare services and health IT, with some later-stage deals in medtech as well, said Marks.
“There’s some real opportu... |
| 15.01.2015 | CTI Life Sciences raises $134 mln in first close of Fund II, boosts staff | - |
| 15.01.2015 | CTI Life Sciences successfully raises new C$ 134 Million venture capital fund | - |
| 15.01.2015 | CTI Life Sciences raises C$134 mln in first close of Fund II, boosts staff | - |
| 28.10.2014 | Knight Therapeutics invests $30 mln in Teralys Capital life sciences fund | - |
| 04.09.2013 | Life sciences company Pharmagen Inc. raises $100K in debt [Startup Roundup] | Have news for the Startup Roundup? Get in touch.who’s getting funded?
Pharmagen Inc., based in Silver Spring, has raised $105,500 in debt, according to SEC filings. The life sciences company is “a distributor of specialty drugs, compounding... |
| 29.06.2010 | SV Life Sciences raises $523m for fifth fund | The sector specialist venture capital firm broke its fund target of $400m, bringing its total funds under management to |
| 11.08.2009 | US life sciences investor Domain Associates closes eighth fund on $500m | The fund will invest in early stage companies in the drug and device sectors with a significant portion of its efforts g |
| 20.02.2007 | SV Life Sciences raises $572m for fourth fund | SV Life Sciences Fund IV had an initial target of €400m and an original cap of €500m, the firm told AltAssets. Havin |
| 13.07.2006 | Life Sciences Partners III closes on €150m | Investors include funds of funds, pension funds, corporates, insurance companies, family offices, and government-linked |
| - | New fund: SV Life Sciences raising $400M for biotech, health IT startups | Boston-based venture capital firm SV Life Sciences is working on its sixth fund, with a fundraising target of $400 million, according to a Form D filing on the U.S. Securities and Exchange Commission’s website. The firm invests in biotech, ... |
| - | CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $276 Million Initial Public Offering | NEW YORK--(BUSINESS WIRE)--Feb 25, 2021--
CM Life Sciences II Inc. (the “ Company ”) announced today that it closed its initial public offering of 27,600,000 units at $10.00 per unit, including 3,600,000 units issued pursuant to the exercis... |
| - | Houston life sciences firm using $7.3M to seed 15 new startups | Houston life sciences investment firm Fannin Innovation Studios recently closed a $7.3 million round which it’ll use to help fund 15 new companies in the next five years, including seven in the coming year. Texas is indeed becoming a hotspo... |
| - | Octopus Ventures backs London-based startup with $50 million to boost automation in life sciences | For far too long, scientists and clinicians have been working with overly complex lab solutions. Equipment and software are disjointed and difficult to orchestrate, while solutions are often too rigid and inappropriate for labs with small g... |
| - | Pfizer spin-off SpringWorks embraces shelved therapies | Pfizer spin-off SpringWorks Therapeutics is carving out a niche repurposing useful molecules from moribund projects. This week, the New York City-based startup brought in $103 million in Series A funding to make that happen.
“SpringsWorks w... |
| - | HeartFlow Raises $215M for AI-Powered Cardiac Test | What You Should Know:
– HeartFlow, Inc., a provider of precision heart care raises $215M in Series F funding round led by Bain Capital Life Sciences with participation from new investor Janus Henderson Investors, and existing investors incl... |